Evidence map›Paper›PMID 39414279›Full record

ArticleBMJ open2024

Association between exposure to proton pump inhibitors and delirium: a descriptive and disproportionality analysis of VigiBase.

Alexandre Decros, Elise-Marie Minoc, Véronique Lelong-Boulouard, Basile Chrétien, Alexandre Meurant, Joachim Alexandre, Charles Dolladille, Cédric Villain

Registry-linked trialAbstract read
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05815550 (Association Between Delirium and Use of Proton Pump Inhibitors), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05815550 completednot on this map

Association Between Delirium and Use of Proton Pump Inhibitors: Analysis of the Global Pharmacovigilance Database

TypeobservationalSponsorUniversity Hospital, CaenRan2022 to 2022Enrolled19,081ConditionsProton Pump Inhibitor Adverse Reaction, Delirium, HyponatremiaArmsPPI
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Proton pump inhibitors and risk of hearing loss; a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Pooled it
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alexandre DecrosService de gériatrie, CHU de CAEN Normandie, Caen, France.
Elise-Marie MinocService de gériatrie, CHU de CAEN Normandie, Caen, France.
Véronique Lelong-BoulouardNormandie Univ, Unicaen, INSERM U1075, COMETE, Caen, France.
Basile ChrétienService de pharmacologie, CHU de Caen Normandie, Caen, France.
Alexandre MeurantService de gériatrie, CHU de CAEN Normandie, Caen, France.
Joachim AlexandreService de pharmacologie, CHU de Caen Normandie, Caen, France.
Charles DolladilleService de pharmacologie, CHU de Caen Normandie, Caen, France.
Cédric VillainService de gériatrie, CHU de CAEN Normandie, Caen, France villain-c@chu-caen.fr.ORCID 0000-0002-2050-2767

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesProton pump inhibitor (PPI) exposure can lead to hyponatraemia, which is a common cause of delirium. An association between PPI exposure and delirium without hyponatraemia has been suggested in the literature. We aimed to describe the association between reports of delirium and PPI exposure and to assess the association between PPI and delirium with and without hyponatraemia.

designA descriptive and disproportionality analysis of claims data.

settingWorld pharmacovigilance database VigiBase between 1 January 1991 and 9 February 2022. PRIMARY AND SECONDARY OUTCOME MEASURES: In the first part, we described reports of delirium for which involvement of a PPI or interactions of PPIs with other drugs were suspected. In the second part, delirium cases and non-cases were used to assess the disproportionality signal using the reporting OR (ROR) for the associations of PPI exposure with delirium or delirium/hyponatraemia co-events.

resultsWe identified 2395 reports of delirium in which involvement of PPI exposure was suspected. Omeprazole, esomeprazole and pantoprazole were the most frequently reported PPIs. Hyponatraemia was present in 11% of the reports. The disproportionality analysis included 1 264 798 reports of adverse drug reactions in patients using PPIs, including 19 081 reports of delirium. We did not find a disproportionality signal for the association between PPI use and delirium (ROR 0.89, 95% CI 0.87 to 0.91). We detected an association of PPI use with delirium/hyponatraemia co-events (ROR 1.53, 95% CI 1.41 to 1.65).

conclusionsMost reports of delirium in which the involvement of PPIs was suspected did not include concomitant hyponatraemia. However, no significant signal of disproportionate reporting of delirium was observed for PPIs compared with other drugs, except in cases of delirium associated with hyponatraemia. Hyponatraemia may be the main mechanism linking PPI exposure with delirium, and this possibility should be further explored in prospective studies. TRIAL REGISTRATION NUMBER: NCT05815550.

Indexed as

DeliriumHyponatremiaPharmacovigilanceProton Pump InhibitorsAdultAdverse Drug Reaction Reporting SystemsAgedAged, 80 and overFemaleHumansMaleMiddle AgedProton Pump InhibitorsAdverse eventsCLINICAL PHARMACOLOGYDeliriumDelirium & cognitive disorders

Identifiers

PMID39414279
PMCPMC11487780

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.